Hosoya Mitsuaki
Department of Pediatrics, Fukushima Medical University School of Medicine.
Nihon Rinsho. 2012 Apr;70(4):625-8.
Subacute sclerosing panencephalitis (SSPE) is a progressive and fatal central nervous system disorder that results from a persistent SSPE virus infection. Compound which inhibits the replication of SSPE virus might be a candidate for the specific drug for SSPE. Out of several compounds which had been tried for the treatment of SSPE, two drugs, i.e., inosiplex and interferon-alpha, were reported to be effective. Those drugs, however, could not cure the disease. Recently, ribavirin therapy has been proposed as novel antiviral chemotherapy for SSPE. By intraventricular administration, ribavirin level in CSF reaches a concentration at which ribavirin could completely inhibit the replication of SSPE virus. Thus, intraventricular ribavirin therapy might eradicate SSPE virus from the CNS and stop the progression of SSPE syndrome. The therapeutic efficacy should be evaluated in the patients who are treated with the therapy at an early stage of SSPE.
亚急性硬化性全脑炎(SSPE)是一种进行性且致命的中枢神经系统疾病,由持续的SSPE病毒感染引起。抑制SSPE病毒复制的化合物可能是SSPE特效药物的候选物。在几种曾尝试用于治疗SSPE的化合物中,据报道两种药物,即肌苷和α-干扰素有效。然而,这些药物无法治愈该疾病。最近,利巴韦林疗法已被提议作为SSPE的新型抗病毒化疗方法。通过脑室内给药,脑脊液中的利巴韦林水平可达到能完全抑制SSPE病毒复制的浓度。因此,脑室内利巴韦林疗法可能从中枢神经系统根除SSPE病毒并阻止SSPE综合征的进展。应在SSPE早期接受该疗法治疗的患者中评估其治疗效果。